Systems and methods for protein expression
OwnerBarbara MERTINS, Thomas FOLLIARDinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a system for the expression of target protein in conjunction with enhancer protein. The enhancer protein may be a viral protein that blocks nucleocytoplasmic transport. Also provided are polynucleotides, vectors, and cells comprising target protein and enhancer protein nucleic acid sequences.
Claims25
1-77. (canceled)
A method for producing a modified eukaryotic cell capable of expressing an NCT inhibitor comprising:
- introducing one or more polynucleotides encoding the NCT inhibitor and an RNA promoter into the cell with a delivery element comprising one or more of a retrovirus, a baculovirus, a helper lipid, and/or a liposome;
- wherein the NCT inhibitor and the RNA promoter are operatively linked, and wherein the NCT inhibitor is selected from the group consisting of a picornavirus leader (L) protein, a picornavirus 2A protease, a rhinovirus 3C protease, a coronavirus ORF6 protein, an ebolavirus VP24 protein, a Venezuelan equine encephalitis virus (VEEV) capsid protein, a herpes simplex virus (HSV) ICP27 protein, and a rhabdovirus matrix (M) protein.
A system comprising:
- (i) one or more polynucleotides encoding an NCT inhibitor and an RNA promoter, wherein the NCT inhibitor and the RNA promoter are operatively linked;
- and
- (ii) a delivery element selected from the group consisting of a retrovirus, a baculovirus, a helper lipid, and/or a liposome;
- wherein the NCT inhibitor is selected from the group consisting of a picornavirus leader (L) protein, a picornavirus 2A protease, a rhinovirus 3C protease, a coronavirus ORF6 protein, an ebolavirus VP24 protein, a Venezuelan equine encephalitis virus (VEEV) capsid protein, a herpes simplex virus (HSV) ICP27 protein, and a rhabdovirus matrix (M) protein.
A modified eukaryotic cell capable of expressing an NCT inhibitor, wherein the NCT inhibitor is selected from the group consisting of a picornavirus leader (L) protein, a picornavirus 2A protease, a rhinovirus 3C protease, a coronavirus ORF6 protein, an ebolavirus VP24 protein, a Venezuelan equine encephalitis virus (VEEV) capsid protein, a herpes simplex virus (HSV) ICP27 protein, and a rhabdovirus matrix (M) protein, wherein a polynucleotide encoding the NCT inhibitor was introduced into the cell by a retrovirus, a baculovirus, a helper lipid, or a liposome, and wherein expression of the nucleocytoplasmic transport (NCT) inhibitor reduces one or more of transcription initiation, transcription termination and polyadenylation, mRNA processing and splicing, mRNA export, translation initiation, protein expression and/or cell stress response.
A system comprising:
- (i) one or more polynucleotides encoding an NCT inhibitor;
- and
- (ii) a delivery element selected from the group consisting of a retrovirus, a baculovirus, a helper lipid, and/or a liposome;
- wherein the NCT inhibitor is selected from the group consisting of a picornavirus leader (L) protein, a picornavirus 2A protease, a rhinovirus 3C protease, a coronavirus ORF6 protein, an ebolavirus VP24 protein, a Venezuelan equine encephalitis virus (VEEV) capsid protein, a herpes simplex virus (HSV) ICP27 protein, and a rhabdovirus matrix (M) protein.
Dependencies are inferred from the claim text.